UKJ Stock Overview
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Opthea Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.39 |
| 52 Week High | AU$0.48 |
| 52 Week Low | AU$0.16 |
| Beta | 0.73 |
| 1 Month Change | -13.39% |
| 3 Month Change | 38.57% |
| 1 Year Change | -3.96% |
| 3 Year Change | -53.53% |
| 5 Year Change | -7.84% |
| Change since IPO | -47.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| UKJ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 10.9% | -0.2% | 0.5% |
| 1Y | -4.0% | -22.8% | 1.3% |
Return vs Industry: UKJ exceeded the German Biotechs industry which returned -23% over the past year.
Return vs Market: UKJ underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| UKJ volatility | |
|---|---|
| UKJ Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UKJ's share price has been volatile over the past 3 months.
Volatility Over Time: UKJ's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 24 | Fred Guerard | opthea.com |
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company’s development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 “VEGFR-3”, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema.
Opthea Limited Fundamentals Summary
| UKJ fundamental statistics | |
|---|---|
| Market cap | €271.77m |
| Earnings (TTM) | -€150.65m |
| Revenue (TTM) | €363.97k |
746.7x
P/S Ratio-1.8x
P/E RatioIs UKJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UKJ income statement (TTM) | |
|---|---|
| Revenue | US$390.44k |
| Cost of Revenue | US$233.89k |
| Gross Profit | US$156.55k |
| Other Expenses | US$161.76m |
| Earnings | -US$161.61m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 40.10% |
| Net Profit Margin | -41,391.02% |
| Debt/Equity Ratio | -385.3% |
How did UKJ perform over the long term?
See historical performance and comparison